Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents

BACKGROUND: Although molecular-targeted agents are still the first choice for advanced hepatocellular carcinoma (HCC) treatment, the therapeutic efficacy of these agents is not satisfactory. Recently, the mammalian target of rapamycin (mTOR) is considered to be a promising molecular target that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Ying-Qi, Li, Bo-An, Feng, Fan, Chen, Yong-Shou, Ren, Yi-Xin, Zhang, Heng, Cao, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394584/
https://www.ncbi.nlm.nih.gov/pubmed/32801748
http://dx.doi.org/10.2147/OTT.S244474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394584/
https://www.ncbi.nlm.nih.gov/pubmed/32801748
http://dx.doi.org/10.2147/OTT.S244474

Ejemplares similares